Clearside Biomedical (CLSDQ)
OTHER OTC:CLSDQ
Top Page
Clearside Biomedical
(OTC:CLSDQ)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.81
▼(-1.59% Downside)
Action:ReiteratedDate:01/29/26
The score is driven primarily by very weak financial performance (large ongoing losses, significant cash burn, and negative equity), reinforced by bearish technicals (price below all key moving averages and negative MACD). Negative corporate events (Chapter 11 process and Nasdaq delisting) further weigh on the outlook, while valuation metrics provide little support due to losses and no stated dividend yield.
Positive Factors
Proprietary delivery technology
Ownership of a specialized SCS Microinjector is a durable competitive asset in posterior-eye therapeutics. It creates differentiation, supports licensing or partnership revenue, and can sustain long-term commercial and collaboration opportunities even if clinical timelines slip.
Negative Factors
Chapter 11 bankruptcy and asset-sale process
A Chapter 11 filing and active asset-sale process fundamentally alter the company's ability to execute long-term plans. Restructuring and potential asset dispositions threaten continuity, reduce value capture for equity holders, and likely end independent commercialization of current programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery technology
Ownership of a specialized SCS Microinjector is a durable competitive asset in posterior-eye therapeutics. It creates differentiation, supports licensing or partnership revenue, and can sustain long-term commercial and collaboration opportunities even if clinical timelines slip.
Read all positive factors
Clearside Biomedical (CLSDQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.52M
Dividend YieldN/A
Average Volume (3M)64.39K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue Growth-56.78%
EPS Growth25.16%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,233,981
10 Day Avg. Volume36,098
30 Day Avg. Volume64,393
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-1.80
Price to Sales (P/S)42.14
P/FCF Ratio-2.73
Enterprise Value/Market Cap37.02
Enterprise Value/Revenue16.88
Enterprise Value/Gross Profit19.73
Enterprise Value/Ebitda-3.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.3
Revenue Forecast (FY)N/A
Clearside Biomedical Business Overview & Revenue Model
Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension f...
How the Company Makes Money
Clearside Biomedical generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing agreements for its drug delivery technology and product candidates. The company may also ear...
Clearside Biomedical Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.33M | 1.66M | 8.23M | 1.33M | 29.57M | 7.89M |
| Gross Profit | 2.85M | 1.51M | 7.87M | 1.12M | 29.57M | 7.89M |
| EBITDA | -14.37M | -24.35M | -23.06M | -29.46M | 554.00K | -17.70M |
| Net Income | -26.00M | -34.35M | -32.48M | -32.95M | 376.00K | -18.21M |
Balance Sheet | ||||||
| Total Assets | 11.64M | 25.13M | 34.02M | 51.30M | 42.90M | 19.32M |
| Cash, Cash Equivalents and Short-Term Investments | 6.80M | 20.02M | 28.92M | 48.42M | 30.44M | 17.29M |
| Total Debt | 61.61M | 52.47M | 43.00M | 35.26M | 675.00K | 1.98M |
| Total Liabilities | 65.59M | 63.98M | 49.93M | 40.70M | 4.93M | 10.56M |
| Stockholders Equity | -53.95M | -38.85M | -15.91M | 10.61M | 37.98M | 8.76M |
Cash Flow | ||||||
| Free Cash Flow | -21.74M | -25.68M | -19.91M | -13.61M | -10.73M | -13.18M |
| Operating Cash Flow | -21.29M | -24.70M | -18.14M | -13.37M | -10.73M | -13.12M |
| Investing Cash Flow | 9.30M | -638.00K | -1.78M | -246.00K | 0.00 | -55.00K |
| Financing Cash Flow | 4.91M | 16.44M | 414.00K | 31.33M | 23.78M | 7.87M |
Clearside Biomedical Technical Analysis
Negative
0.82
Price Trends
0.67
Negative
1.08
Negative
3.89
Negative
Market Momentum
-0.05
Positive
39.44
Neutral
38.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSDQ, the sentiment is Negative. The current price of 0.82 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.67, and below the 200-day MA of 3.89, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.44 is Neutral, neither overbought nor oversold. The STOCH value of 38.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSDQ.
Clearside Biomedical Risk Analysis
Clearside Biomedical disclosed 69 risk factors in its most recent earnings report. Clearside Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clearside Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
39 Underperform | $1.52M | -0.87 | 55.47% | ― | -56.78% | 25.16% | |
| ― | $6.30M | -5.39 | ― | ― | ― | 65.45% | |
67 Neutral | $47.45M | -3.44 | -16.25% | ― | 12.71% | 79.93% | |
47 Neutral | $72.21M | -1.05 | -602.02% | ― | ― | 93.84% | |
45 Neutral | $6.72M | -0.28 | -257.81% | ― | ― | 72.88% | |
44 Neutral | $5.05M | >-0.01 | -389.34% | ― | ― | 99.02% |
* Healthcare Sector Average
CLSDQ
Clearside Biomedical
0.26
-13.69
-98.11%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.45
-2.51
-50.60%
APVO
Aptevo Therapeutics
4.17
-492.63
-99.16%
PCSA
Processa Pharmaceuticals
2.60
-4.90
-65.29%
RLYB
Rallybio
8.40
3.76
81.03%
CING
Cingulate Inc
6.01
1.85
44.47%
Clearside Biomedical Corporate Events
Business Operations and StrategyFinancial DisclosuresLegal Proceedings
Clearside Biomedical Advances Bankruptcy Asset Sale Process
Negative
Dec 29, 2025
Clearside Biomedical, Inc., which filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025, advanced its court-supervised sale process in December 2025 by securing approval of auctio...
Delistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
Clearside Biomedical Delists from Nasdaq Amid Bankruptcy
Negative
Dec 8, 2025
On December 8, 2025, Clearside Biomedical filed a Form 25 with the SEC to delist its common stock from Nasdaq and terminate its registration under the Exchange Act, following a voluntary Chapter 11 bankruptcy filing. The stock was suspended from N...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.